Cabaletta Historical Income Statement

CABA Stock

USD 3.11 0.19 5.76%

Historical analysis of Cabaletta Bio income statement accounts such as Selling General Administrative of 10.9 M, Research Development of 58.2 M or Total Operating Expenses of 78.4 M can show how well Cabaletta Bio performed in making a profits. Evaluating Cabaletta Bio income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Cabaletta Bio's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Cabaletta Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cabaletta Bio is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabaletta Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.

About Cabaletta Income Statement Analysis

Cabaletta Bio Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Cabaletta Bio shareholders. The income statement also shows Cabaletta investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Cabaletta Bio Income Statement Chart

At present, Cabaletta Bio's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 58.2 M, whereas Selling General Administrative is forecasted to decline to about 10.9 M.

Selling General Administrative Total Operating Expenses Other Operating Expenses

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Cabaletta Bio. It is also known as Cabaletta Bio overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Cabaletta Bio's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Cabaletta Bio current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cabaletta Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.At present, Cabaletta Bio's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 58.2 M, whereas Selling General Administrative is forecasted to decline to about 10.9 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	46.3M	54.1M	74.7M	78.4M
Research Development	32.5M	39.3M	55.4M	58.2M

Total Operating Expenses Research Development

Cabaletta Bio income statement Correlations

	Selling General Administrative	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Total Operating Expenses	Income Before Tax	Net Income	Net Interest Income	Interest Income	Depreciation And Amortization	Other Operating Expenses	Ebitda	Total Other Income Expense Net	Income Tax Expense	Gross Profit	Cost Of Revenue	Reconciled Depreciation	Non Operating Income Net Other	Selling And Marketing Expenses
Selling General Administrative		-0.95	-0.95	-0.95	0.89	0.93	-0.95	-0.95	0.62	0.62	0.95	0.98	-0.91	0.9	-0.73	-0.67	0.7	0.91	0.87	-0.46
Operating Income	-0.95		1.0	1.0	-0.99	-1.0	1.0	1.0	-0.8	-0.8	-0.93	-0.96	0.99	-0.95	0.69	0.71	-0.72	-0.94	-0.88	0.71
Net Income From Continuing Ops	-0.95	1.0		1.0	-0.98	-0.99	1.0	1.0	-0.76	-0.76	-0.93	-0.96	0.98	-0.94	0.69	0.72	-0.73	-0.93	-0.89	0.68
Ebit	-0.95	1.0	1.0		-0.99	-1.0	1.0	1.0	-0.8	-0.8	-0.93	-0.96	0.99	-0.95	0.69	0.71	-0.72	-0.94	-0.88	0.71
Research Development	0.89	-0.99	-0.98	-0.99		0.99	-0.98	-0.98	0.84	0.84	0.88	0.94	-1.0	0.94	-0.64	-0.72	0.72	0.93	0.88	-0.78
Total Operating Expenses	0.93	-1.0	-0.99	-1.0	0.99		-0.99	-0.99	0.81	0.81	0.92	0.95	-0.99	0.96	-0.69	-0.71	0.71	0.92	0.87	-0.74
Income Before Tax	-0.95	1.0	1.0	1.0	-0.98	-0.99		1.0	-0.76	-0.76	-0.93	-0.96	0.98	-0.94	0.69	0.72	-0.73	-0.93	-0.89	0.67
Net Income	-0.95	1.0	1.0	1.0	-0.98	-0.99	1.0		-0.77	-0.77	-0.92	-0.96	0.99	-0.94	0.67	0.72	-0.73	-0.93	-0.89	0.68
Net Interest Income	0.62	-0.8	-0.76	-0.8	0.84	0.81	-0.76	-0.77		1.0	0.63	0.69	-0.83	0.85	-0.53	-0.43	0.41	0.7	0.61	-0.93
Interest Income	0.62	-0.8	-0.76	-0.8	0.84	0.81	-0.76	-0.77	1.0		0.63	0.69	-0.83	0.85	-0.53	-0.43	0.41	0.7	0.61	-0.93
Depreciation And Amortization	0.95	-0.93	-0.93	-0.93	0.88	0.92	-0.93	-0.92	0.63	0.63		0.9	-0.88	0.94	-0.87	-0.63	0.66	0.81	0.76	-0.51
Other Operating Expenses	0.98	-0.96	-0.96	-0.96	0.94	0.95	-0.96	-0.96	0.69	0.69	0.9		-0.95	0.89	-0.66	-0.73	0.75	0.97	0.93	-0.53
Ebitda	-0.91	0.99	0.98	0.99	-1.0	-0.99	0.98	0.99	-0.83	-0.83	-0.88	-0.95		-0.93	0.62	0.72	-0.73	-0.95	-0.9	0.75
Total Other Income Expense Net	0.9	-0.95	-0.94	-0.95	0.94	0.96	-0.94	-0.94	0.85	0.85	0.94	0.89	-0.93		-0.83	-0.58	0.59	0.82	0.75	-0.74
Income Tax Expense	-0.73	0.69	0.69	0.69	-0.64	-0.69	0.69	0.67	-0.53	-0.53	-0.87	-0.66	0.62	-0.83		0.49	-0.5	-0.55	-0.5	0.37
Gross Profit	-0.67	0.71	0.72	0.71	-0.72	-0.71	0.72	0.72	-0.43	-0.43	-0.63	-0.73	0.72	-0.58	0.49		-1.0	-0.83	-0.78	0.35
Cost Of Revenue	0.7	-0.72	-0.73	-0.72	0.72	0.71	-0.73	-0.73	0.41	0.41	0.66	0.75	-0.73	0.59	-0.5	-1.0		0.83	0.77	-0.32
Reconciled Depreciation	0.91	-0.94	-0.93	-0.94	0.93	0.92	-0.93	-0.93	0.7	0.7	0.81	0.97	-0.95	0.82	-0.55	-0.83	0.83		0.96	-0.56
Non Operating Income Net Other	0.87	-0.88	-0.89	-0.88	0.88	0.87	-0.89	-0.89	0.61	0.61	0.76	0.93	-0.9	0.75	-0.5	-0.78	0.77	0.96		-0.48
Selling And Marketing Expenses	-0.46	0.71	0.68	0.71	-0.78	-0.74	0.67	0.68	-0.93	-0.93	-0.51	-0.53	0.75	-0.74	0.37	0.35	-0.32	-0.56	-0.48

Click cells to compare fundamentals

Cabaletta Bio Account Relationship Matchups

Cabaletta Bio income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Selling General Administrative	7.0M	12.5M	13.8M	14.8M	19.2M	10.9M
Operating Income	(18.7M)	(33.8M)	(46.3M)	(54.1M)	(74.7M)	(70.9M)
Net Income From Continuing Ops	(16.9M)	(33.3M)	(46.3M)	(53.0M)	(67.7M)	(64.3M)
Ebit	(18.7M)	(33.8M)	(46.3M)	(54.1M)	(74.7M)	(70.9M)
Research Development	11.7M	21.4M	32.5M	39.3M	55.4M	58.2M
Total Operating Expenses	18.7M	33.8M	46.3M	54.1M	74.7M	78.4M
Income Before Tax	(16.9M)	(33.3M)	(46.3M)	(53.0M)	(67.7M)	(64.3M)
Net Income Applicable To Common Shares	(22.3M)	(33.3M)	(46.3M)	(53.0M)	(47.7M)	(45.3M)
Net Income	(15.1M)	(32.5M)	(45.5M)	(51.8M)	(67.7M)	(64.3M)
Net Interest Income	1.7M	494K	24K	1.2M	7.0M	7.3M
Interest Income	1.7M	494K	24K	1.2M	7.0M	7.3M
Depreciation And Amortization	104K	354K	733K	1.2M	1.4M	1.5M
Other Operating Expenses	18.7M	33.8M	46.3M	54.1M	74.7M	42.9M
Ebitda	(18.6M)	(33.5M)	(45.6M)	(53.0M)	(73.2M)	(69.6M)
Total Other Income Expense Net	1.7M	494K	24K	1.2M	7.0M	7.3M
Income Tax Expense	(1.8M)	(848K)	(757K)	(1.2M)	(1.0M)	(1.1M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Cabaletta Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cabaletta Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cabaletta Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cabaletta Bio Stock:

How To Invest In Cabaletta

Details

Is Cabaletta Stock a good investment?

Details

What is Cabaletta Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Cabaletta Stock refer to our How to Trade Cabaletta Stock guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cabaletta Bio. If investors know Cabaletta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cabaletta Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.16)

Return On Assets

(0.31)

Return On Equity

(0.48)

The market value of Cabaletta Bio is measured differently than its book value, which is the value of Cabaletta that is recorded on the company's balance sheet. Investors also form their own opinion of Cabaletta Bio's value that differs from its market value or its book value, called intrinsic value, which is Cabaletta Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cabaletta Bio's market value can be influenced by many factors that don't directly affect Cabaletta Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cabaletta Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cabaletta Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cabaletta Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cabaletta Historical Income Statement

About Cabaletta Income Statement Analysis

Cabaletta Bio Income Statement Chart

Total Operating Expenses

Other Operating Expenses

Cabaletta Bio income statement Correlations

Cabaletta Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cabaletta Bio income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Expense	Selling General Administrative
Operating Income	Net Income From Continuing Ops
Ebit	Research Development
Total Operating Expenses	Income Before Tax
Net Income Applicable To Common Shares	Net Income
Net Interest Income	Interest Income
Depreciation And Amortization	Total Revenue
Other Operating Expenses	Ebitda
Total Other Income Expense Net	Income Tax Expense
Gross Profit	Cost Of Revenue
Reconciled Depreciation	Non Operating Income Net Other
Selling And Marketing Expenses

Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebit	+ 1.0	Net Income From Continuing Ops
Income Before Tax	+ 1.0	Net Income From Continuing Ops

Cost Of Revenue	- 1.0	Gross Profit
Ebitda	- 1.0	Research Development
Total Operating Expenses	- 1.0	Ebit
Total Operating Expenses	- 1.0	Operating Income
Ebitda	- 0.99	Total Operating Expenses
Net Income	- 0.99	Total Operating Expenses